Table 1.
Baseline characteristics of gout patients using vs not using colchicine before and after inverse probability weighting
| Variable | Colchicine (n = 446) | No colchicine (n = 276) | P value | After IPW | P value | Standardized mean difference | |
|---|---|---|---|---|---|---|---|
| Colchicine | No colchicine | ||||||
| Age, years | 64 ± 9 | 64 ± 10 | 0.92 | 64.5 ± 9.3 | 64.8 ± 9.2 | 0.75 | 0.03 |
| Race | 0.68 | 0.99 | 0.003 | ||||
| White | 234 (52.6%) | 141 (51.3%) | 280.2 (53.2) | 282.9 (53.3) | |||
| Black | 205 (46.1%) | 128 (46.5%) | 239.2 (45.4) | 239.7 (45.2) | |||
| Asian | 6 (1.3%) | 6 (2.2%) | 7.6 (1.4) | 7.6 (1.4) | |||
| Ethnicity | 0.72 | 0.95 | 0.006 | ||||
| Hispanic | 48 (10.8%) | 27 (9.9%) | 52.0 (9.8) | 52.0 (9.8) | |||
| Non-Hispanic | 397 (89.2%) | 245 (90.1%) | 478.3 (90.2) | 478.3 (90.2) | |||
| Body mass index, kg/m2 | 30.2 ± 5.8 | 30.2 ± 6.5 | 0.91 | 30.2 ± 6.4 | 30.2 ± 6.4 | 0.97 | 0.003 |
| Diabetes mellitus | 106 (23.8%) | 67 (24.3%) | 0.88 | 130.2 (24.6) | 130.2 (24.6) | 0.82 | 0.021 |
| Hypertension | 363 (81.6%) | 222 (80.4%) | 0.70 | 448.9 (84.7) | 448.9 (84.7) | 0.83 | 0.02 |
| Systolic blood pressure, mm Hg | 137 ± 20 | 140 ± 20 | 0.07 | 137.8 ± 20.6 | 137.8 ± 20.6 | 0.92 | 0.01 |
| Diastolic blood pressure, mm Hg | 80 ± 11 | 81 ± 12 | 0.23 | 79.82 ± 12.8 | 79.82 ± 12.8 | 0.95 | 0.006 |
| Hyperlipidemia | 224 (50.9%) | 118 (42.9%) | 0.04 | 273.2 (51.5) | 273.2 (51.5) | 0.93 | 0.008 |
| Chronic kidney disease | 116 (26.2%) | 72 (26.6%) | 0.92 | 151.4 (28.6) | 151.4 (28.6) | 0.92 | 0.01 |
| Serum creatinine, mg/dL | 1.26 ± 0.50 | 1.27 ± 0.60 | 0.73 | 1.26 ± 0.54 | 1.26 ± 0.54 | 0.96 | 0.004 |
| Glomerular filtration rate, mL/min | 71 ± 23 | 72 ± 24 | 0.74 | 71.4 ± 22.1 | 71.4 ± 22.1 | 0.99 | 0.001 |
| History of tobacco use | 330 (74.3%) | 197 (73.2%) | 0.75 | 400.4 (75.5) | 400.4 (75.5) | 0.98 | 0.003 |
| Active tobacco use | 98 (22.0%) | 60 (22.1%) | 0.97 | 116.9 (22.0) | 116.9 (22.0) | 0.98 | 0.003 |
| Allopurinol use | 102 (22.9%) | 54 (19.6%) | 0.29 | 110.9 (20.9) | 110.9 (20.9) | 0.93 | 0.009 |
| NSAID use | 184 (41.3%) | 117 (42.4%) | 0.76 | 229.7 (43.3) | 229.7 (43.3) | 0.99 | < 0.001 |
| Aspirin use | 90 (20.2%) | 64 (23.2%) | 0.34 | 114.0 (21.5) | 114.0 (21.5) | 0.89 | 0.012 |
| Statin use | 122 (27.4%) | 80 (29.2%) | 0.59 | 164.4 (31.0) | 164.4 (31.0) | 0.92 | 0.009 |
| ACE inhibitor use | 174 (39.0%) | 80 (29.0%) | 0.006 | 209.0 (39.4) | 209.0 (39.4) | 0.85 | 0.018 |
| β-blocker use | 124 (27.8%) | 63 (22.8%) | 0.14 | 146.5 (27.6) | 146.5 (27.6) | 0.99 | < 0.001 |
| Any antihypertensive use | 317 (71.1%) | 175 (63.4%) | 0.03 | 387.1 (73.0) | 387.1 (73.0) | 0.86 | 0.017 |
Continuous data are shown as mean ± standard deviation and compared using the independent Student’s t-test. Categorical data are shown as frequency (proportion) and compared using the χ2 test.
ACE, angiotensin-converting enzyme; IPW, inverse probability weighting; NSAID, nonsteroidal anti-inflammatory drug.